US 10,828,345 B2 | Use of a VEGF antagonist to treat angiogenic eye disorders

Please sign up or log in to access the advanced features of
Ex Parte Enterprise.

or Log in

General

US 10,828,345 B2

Use of a VEGF antagonist to treat angiogenic eye disorders

Tech Center:

1600 Biotechnology and Organic Chemistry

Examiner:

Christine J Saoud

Art Unit:

1647 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology

Agent:

Regeneron Pharmaceuticals, Inc

Inventors:

George D. Yancopoulos

Assignee:

REGENERON PHARMACEUTICALS, INC.

Priority:

01/13/11

Filed:

10/12/18

Granted:

11/10/20

Expiration:

01/13/31

Abstract

The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

General

Analytics

Cases

Patent Assignments

Citations